title: Author reply 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
authors.affiliation: Oncology Unit, Eastern Health, Melbourne, Victoria, Australia.
authors.forename: A J
authors.initials: AJ
authors.lastname: Lomax
authors.affiliation: Oncology Unit, Eastern Health, Melbourne, Victoria, Australia.|Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Parente
authors.affiliation: Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.|Endocrinology Unit, Eastern Health, Melbourne, Victoria, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Gilfillan
authors.affiliation: Faculty of Health, Deakin University, Melbourne, Victoria, Australia.
authors.forename: P M
authors.initials: PM
authors.lastname: Livingston
authors.affiliation: Oncology Unit, Eastern Health, Melbourne, Victoria, Australia.|Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
authors.forename: I D
authors.initials: ID
authors.lastname: Davis
authors.affiliation: Oncology Unit, Eastern Health, Melbourne, Victoria, Australia.|Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Pezaro
mesh_terms: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal